↓ Skip to main content

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro , in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway

Overview of attention for article published in Oncotarget, October 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro , in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway
Published in
Oncotarget, October 2015
DOI 10.18632/oncotarget.6153
Pubmed ID
Authors

Azadeh Cheraghchi-Bashi, Christine A. Parker, Ed Curry, Jean-Frederic Salazar, Hatice Gungor, Azeem Saleem, Paula Cunnea, Nona Rama, Cristian Salinas, Gordon B. Mills, Shannon R. Morris, Rakesh Kumar, Hani Gabra, Euan A. Stronach

Abstract

Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker signatures correlating with effects of GSK2141795 were developed using in vitro and in vivo models, well characterised for related molecular, phenotypic and imaging endpoints. Signatures were validated in temporally paired biopsies from patients treated with GSK2141795 in a clinical study. GSK2141795 caused growth-arrest as single agent in vitro, enhanced cisplatin-induced apoptosis in vitro and reduced tumour volume in combination with platinum in vivo. GSK2141795 treatment in vitro and in vivo resulted in ~50-90% decrease in phospho-PRAS40 and 20-80% decrease in fluoro-deoxyglucose (FDG) uptake. Proteomic analysis of GSK2141795 in vitro and in vivo identified a signature of pathway inhibition including changes in AKT and p38 phosphorylation and total Bim, IGF1R, AR and YB1 levels. In patient biopsies, prior to treatment with GSK2141795 in a phase 1 clinical trial, this signature was predictive of post-treatment changes in the response marker CA125. Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 2%
Italy 1 2%
Unknown 41 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 23%
Student > Ph. D. Student 6 14%
Student > Master 6 14%
Student > Bachelor 4 9%
Professor > Associate Professor 3 7%
Other 8 19%
Unknown 6 14%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 13 30%
Medicine and Dentistry 11 26%
Agricultural and Biological Sciences 5 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Business, Management and Accounting 1 2%
Other 4 9%
Unknown 6 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2015.
All research outputs
#15,686,478
of 23,310,485 outputs
Outputs from Oncotarget
#6,773
of 14,403 outputs
Outputs of similar age
#167,844
of 284,975 outputs
Outputs of similar age from Oncotarget
#407
of 842 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 14,403 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,975 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 842 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.